Pharmacosmos Holding As v. Mylan Laboratories Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pharmacosmos Holding A/S, Pharmacosmos A/S, and Pharmacosmos Therapeutics Inc. (Denmark/Delaware)
  • Defendant: Mylan Laboratories Ltd. (India)
  • Plaintiff’s Counsel: Chiesa Shahinian & Giantomasi PC
• Case Identification: 2:26-cv-04946, D.N.J., 05/01/2026
• Venue Allegations: Venue is alleged to be proper because the defendant, a foreign corporation, may be sued in any judicial district where personal jurisdiction exists.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Injectafer® infringes patents covering methods for treating iron deficiency while reducing the severity of drug-induced side effects.
• Technical Context: The technology relates to intravenous iron-carbohydrate complexes used to treat iron deficiency anemia, and specifically to dosing regimens that mitigate the risk of hypophosphatemia (abnormally low serum phosphate levels).
• Key Procedural History: This is a Hatch-Waxman action triggered by Mylan's ANDA No. 212572. The complaint notes that Mylan previously settled litigation with Vifor (International) AG and American Regent, Inc. concerning the same ANDA, resulting in a license for Mylan to launch its generic product on July 1, 2026. The complaint also references a separate, ongoing lawsuit filed by Pharmacosmos against the brand drug (Injectafer®) NDA holder, Daiichi Sankyo, Inc., alleging infringement of the same asserted patents.

Case Timeline

Date	Event
2018-10-29	Priority Date for ’934 and ’486 Patents
2019-05-07	Mylan files ANDA No. 212572 (on or before this date)
2020-02-01	Injectafer® label revised to include hypophosphatemia warnings
2023-05-31	Injectafer® label revised with further warnings
2025-01-03	Injectafer® label most recently revised ("2025 Injectafer Label")
2025-05-13	U.S. Patent No. 12,295,934 issues
2025-05-20	U.S. Patent No. 12,303,486 issues
2025-09-22	Pharmacosmos files suit against Daiichi Sankyo, Inc.
2026-03-11	Pharmacosmos sends notice letter to Mylan
2026-03-20	Mylan receives notice letter (on or about this date)
2026-04-09	Mylan responds to notice letter
2026-05-01	Complaint filed
2026-07-01	Mylan's licensed launch date for ANDA Product

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,295,934 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued May 13, 2025)

The Invention Explained

• Problem Addressed: The patent addresses the discovery that repeated intravenous (IV) administration of ferric carboxymaltose (FCM) can cause an "auto-synergistic" and clinically significant increase in the hormone iFGF23, leading to severe hypophosphatemia (low serum phosphate) (Compl. ¶¶27-28; '934 Patent, col. 3:19-26). Prior to this discovery, FCM-induced hypophosphatemia was considered transient and clinically irrelevant (Compl. ¶26; '934 Patent, col. 2:26-47).
• The Patented Solution: The patent discloses methods to reduce the severity of these side effects by implementing a specific monitoring and treatment protocol ('934 Patent, abstract). The method requires measuring a subject's serum phosphate levels before administering a subsequent dose of FCM. If the subject has hypophosphatemia, the condition is treated before the next FCM dose is administered, thereby preventing the auto-synergistic effect and reducing the severity of complications like reduced muscle function and increased bone turnover (Compl. ¶36; '934 Patent, col. 3:40-54).
• Technical Importance: This invention provided a method to safely administer repeated courses of high-dose IV iron therapy by actively managing a newly discovered, serious side effect that was previously misunderstood by the medical community (Compl. ¶¶28, 38).

Key Claims at a Glance

• The complaint asserts claims 1-60, focusing on independent claims 1 and 31 (Compl. ¶52).
• Independent Claim 1 recites a method of reducing the severity of side effects, comprising the steps of:
  • administering a first dose of FCM;
  • determining a subject needs a further dose;
  • measuring the subject's serum phosphate levels;
  • if hypophosphatemia is found, treating it as medically indicated prior to the next dose; and
  • administering the further dose of FCM (Compl. ¶56).
• Independent Claim 31 recites a similar method, but with a different sequence for the pre-dosing steps:
  • administering a first dose of FCM;
  • determining a subject needs a further dose;
  • first treating the subject with a medically indicated treatment for hypophosphatemia;
  • then measuring the subject's serum phosphate levels; and
  • administering the further dose of FCM (Compl. ¶66).

U.S. Patent No. 12,303,486 - Treating Iron Deficiency with Ferric Carboxymaltose (Issued May 20, 2025)

The Invention Explained

• Problem Addressed: The patent, which shares a specification with the '934 Patent, addresses the problem that FCM frequently causes "clinically significant, symptomatic hypophosphatemia," a risk that was not appreciated in the prior art (Compl. ¶42; '486 Patent, col. 2:26-47).
• The Patented Solution: The patent claims a method of "reducing the risk of symptomatic hypophosphatemia" associated with repeated FCM treatment ('486 Patent, claim 1). The method is functionally identical to that of the '934 patent: it requires evaluating a subject's serum phosphate levels and correcting any identified hypophosphatemia before administering a subsequent dose, thereby mitigating the risk of FGF23-mediated side effects (Compl. ¶41; '486 Patent, col. 3:40-54).
• Technical Importance: The invention established a protocol to manage and reduce the risk of symptomatic side effects that were previously unknown and unaddressed in conventional treatment regimens (Compl. ¶42).

Key Claims at a Glance

• The complaint asserts claims 1-29, focusing on independent claim 1 (Compl. ¶87).
• Independent Claim 1 recites a method of reducing the risk of symptomatic hypophosphatemia, comprising the steps of:
  • administering a first dose of FCM;
  • determining a subject needs a further dose;
  • measuring the subject's serum phosphate levels;
  • if hypophosphatemia is found, treating it as medically indicated prior to the next dose; and
  • administering the further dose of FCM (Compl. ¶91).
• The language of this claim is identical to Claim 1 of the '934 Patent, except for the preamble, which recites "reducing risk of symptomatic hypophosphatemia" instead of "reducing severity of side effects."

III. The Accused Instrumentality

Product Identification

• Mylan's generic ferric carboxymaltose injection, to be marketed under ANDA No. 212572 (Compl. ¶1).

Functionality and Market Context

• The accused product is a generic version of Injectafer® and contains the same active ingredient, ferric carboxymaltose (Compl. ¶57). It is indicated for treating iron deficiency anemia (IDA) and iron deficiency in patients with heart failure (Compl. ¶57). The infringement allegation is not based on the product itself, but on the method of its use. The complaint alleges that the product's label ("Mylan's Label") will be "materially the same" as the current 2025 Injectafer® label and will instruct healthcare providers to use the product in a manner that infringes the asserted patents (Compl. ¶¶18, 46, 54). Mylan has a license from the brand manufacturer to launch its generic product on July 1, 2026, and is allegedly preparing to be "first to market" (Compl. ¶¶22, 44).

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'934 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose to a subject in need thereof, said method comprising,	The Mylan Label allegedly instructs warnings and treatment steps for hypophosphatemia, which constitutes a method of reducing its severity during repeated treatment for iron deficiency (Compl. ¶¶57-58).	¶58	col. 12:35-43
administering a dose of ferric carboxymaltose to said subject;	The Mylan Label allegedly instructs administering doses of ferric carboxymaltose for treating IDA (Compl. ¶59).	¶59	col. 11:51-54
determining that said subject needs a further dose of ferric carboxymaltose;	The Mylan Label allegedly instructs that treatment may be repeated if IDA reoccurs and that phosphate levels should be checked prior to a repeat course of treatment (Compl. ¶60).	¶60	col. 12:10-18
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels,	The Mylan Label allegedly instructs physicians to "check serum phosphate levels prior to a repeat course of treatment" in at-risk patients (Compl. ¶61).	¶61	col. 14:1-4
and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and	The Mylan Label allegedly instructs physicians to "treat hypophosphatemia as medically indicated" (Compl. ¶62).	¶62	col. 12:26-30
administering the further dose of ferric carboxymaltose to said subject.	The Mylan Label allegedly instructs that treatment "may be repeated," constituting the administration of a further dose (Compl. ¶63).	¶63	col. 12:31-34

'486 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of reducing risk of symptomatic hypophosphatemia associated with repeated treatment of iron deficiency with ferric carboxymaltose in a subject in need thereof, said method comprising,	The Mylan Label allegedly warns of symptomatic hypophosphatemia and instructs monitoring/treatment steps, thereby instructing a method to reduce the risk (Compl. ¶¶92-93).	¶93	col. 12:35-43
administering a dose of ferric carboxymaltose to said subject;	The Mylan Label allegedly instructs administering doses of ferric carboxymaltose (Compl. ¶94).	¶94	col. 11:51-54
determining that said subject needs a further dose of ferric carboxymaltose;	The Mylan Label allegedly instructs that treatment can be repeated if IDA reoccurs and that phosphate levels should be checked, leading to a determination of need (Compl. ¶95).	¶95	col. 12:10-18
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels,	The Mylan Label allegedly instructs physicians to "monitor" and "check" serum phosphate levels before a repeat course of treatment (Compl. ¶96).	¶96	col. 14:1-4
and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose; and	The Mylan Label allegedly instructs physicians to "treat hypophosphatemia as medically indicated" (Compl. ¶97).	¶97	col. 12:26-30
administering the further dose of ferric carboxymaltose to said subject.	The Mylan Label allegedly instructs that treatment "may be repeated," which constitutes the administration of a further dose (Compl. ¶98).	¶98	col. 12:31-34

Identified Points of Contention

• Scope Questions: A central issue may be whether the instructions on Mylan's label, which allegedly direct physicians to "monitor" or "check" phosphate levels, meet the affirmative claim step of "measuring" (Compl. ¶¶61, 96). A further question is whether the conditional limitation "if said subject has hypophosphatemia, treating..." is met by a label that instructs physicians to "treat hypophosphatemia as medically indicated" (Compl. ¶¶62, 97).
• Technical Questions: The infringement theory is based entirely on label-based inducement. A key question for the court will be whether the complaint sufficiently alleges that healthcare professionals following the instructions on Mylan's label will inevitably perform all the steps of the claimed method in the sequence required by the claims. This is particularly relevant for the different sequences recited in Claim 1 and Claim 31 of the '934 patent.

V. Key Claim Terms for Construction

The Term: "treating the hypophosphatemia as medically indicated" ('934 Patent, Claim 1; '486 Patent, Claim 1)

• Context and Importance: This term is critical because the infringement allegation hinges on the product label instructing this step (Compl. ¶¶62, 97). The definition of what constitutes "treating" and what is "medically indicated" will be central to determining whether following the label constitutes infringement. Practitioners may focus on this term because its potential ambiguity could be a key non-infringement argument.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification suggests that treatment can include administering additional drugs like vitamin D or phosphates, which could support a broad interpretation covering various interventions ('934 Patent, col. 15:55-65; '934 Patent, col. 16:25-34).
  • Evidence for a Narrower Interpretation: A defendant may argue that "treating" implies a specific, prescribed corrective action beyond mere observation or general advice. The patent's focus on "correcting" hypophosphatemia before a further dose could be argued to require a confirmed resolution of the condition, not just an attempt to treat ('934 Patent, col. 12:26-30).

The Term: "reducing severity of side effects" vs. "reducing risk of symptomatic hypophosphatemia" (preambles of '934 Patent, Claim 1 and '486 Patent, Claim 1)

• Context and Importance: The preambles of the lead independent claims of the two asserted patents are different. A significant legal dispute may arise over whether these preambles are legally limiting on the scope of the claims. If they are found to be limiting, Pharmacosmos would need to prove not only that the claimed steps are performed, but also that they achieve the stated purpose of "reducing severity" or "reducing risk."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation (or Non-Limiting): Pharmacosmos may argue the body of the claims defines the invention and the preambles merely state an intended result. The specification describes the methods as achieving both outcomes, suggesting they are intertwined aspects of the same inventive concept ('934 Patent, col. 12:35-43).
  • Evidence for a Narrower Interpretation (or Limiting): A defendant could argue that the terms set distinct standards. For example, "reducing risk" might be argued to require a higher burden of proof (a prophylactic effect) than "reducing severity" (a mitigating effect). The patent's explicit choice to use different language in the preambles of related patents may suggest an intentional distinction.

VI. Other Allegations

• Indirect Infringement: The complaint's primary theory is induced infringement under 35 U.S.C. § 271(b). It alleges that Mylan, with knowledge of the patents, will sell its ANDA product with a label that "actively and knowingly" instructs and encourages healthcare providers to perform the patented methods (Compl. ¶¶52, 87). The complaint also alleges infringement under 35 U.S.C. § 271(e)(2) based on the submission of the ANDA itself for a use claimed in the patents (Compl. ¶¶80-81, 105-106).
• Willful Infringement: The complaint alleges that Mylan has had actual knowledge of the asserted patents at least since receiving a notice letter on or about March 20, 2026 (Compl. ¶¶76, 101). It further alleges Mylan "should have known" of the infringement risk since September 22, 2025, when Pharmacosmos filed a public lawsuit on the same patents against the brand manufacturer (Compl. ¶¶77, 102). These allegations form the basis for a claim of willful infringement.

VII. Analyst’s Conclusion: Key Questions for the Case

• A core issue will be one of claim construction and label interpretation: Can the general instructions on a generic drug label to "monitor," "check," and "treat as medically indicated" be construed to meet the specific, ordered, and conditional steps of the asserted method claims? The outcome may depend on whether a court finds that following the label's guidance inevitably results in performing the patented method.
• A second key question will be one of intent for inducement: Given that this is a Hatch-Waxman case premised on future conduct, the central evidentiary challenge will be for the plaintiff to prove that the defendant, by seeking approval for its proposed label, possessed the specific intent to encourage infringing acts, particularly in light of the defendant's asserted defenses of non-infringement and invalidity.
• A dispositive legal question may be the limiting nature of the preamble: Will the court determine that the differing preambles of the '934 and '486 patents ("reducing severity" vs. "reducing risk") are legally limiting? If so, this could create different standards of proof for each patent and complicate the infringement analysis.